annb0t
Top 20
SYDNEY, April 4, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of new data for both of its pipeline molecules, paxalisib and EVT801, at the upcoming Annual Meeting of the American Association for Cancer Research (AACR), held in Orlando, FL, from 14 â 19 April 2023. Kazia Therapeutics Limited Logo (PRNewsfoto/Kazia Therapeutics Limited)
In total, there will be five presentations...
>>> Read more: KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING
In total, there will be five presentations...
>>> Read more: KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING
